Caas Capital Management LP Acquires New Stake in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS)

Caas Capital Management LP bought a new position in shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 59,000 shares of the company's stock, valued at approximately $1,470,000. Caas Capital Management LP owned about 0.11% of Kestra Medical Technologies as of its most recent SEC filing.

Separately, Brown Advisory Inc. purchased a new stake in Kestra Medical Technologies in the first quarter valued at approximately $13,716,000.

Kestra Medical Technologies Stock Up 3.5%

Shares of KMTS stock traded up $0.52 during mid-day trading on Monday, reaching $15.43. The stock had a trading volume of 219,449 shares, compared to its average volume of 254,476. Kestra Medical Technologies, Ltd. has a 12-month low of $14.02 and a 12-month high of $26.15. The firm's 50-day moving average is $19.53.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its quarterly earnings results on Monday, April 14th. The company reported ($1.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.61). During the same quarter last year, the firm posted ($1.18) earnings per share.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on KMTS. Wolfe Research assumed coverage on Kestra Medical Technologies in a research note on Monday, March 31st. They issued an "outperform" rating and a $29.00 price objective for the company. Wells Fargo & Company assumed coverage on Kestra Medical Technologies in a report on Monday, March 31st. They set an "overweight" rating and a $28.00 price target for the company. The Goldman Sachs Group decreased their price target on Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating for the company in a report on Wednesday, April 16th. Bank of America assumed coverage on Kestra Medical Technologies in a report on Monday, March 31st. They set a "buy" rating and a $30.00 price target for the company. Finally, Piper Sandler began coverage on Kestra Medical Technologies in a report on Monday, March 31st. They set an "overweight" rating and a $27.00 price target for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $27.50.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.